NCT02010827

Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: All
• Age: 35 Years – 80 Years
• Healthy volunteers: Accepted

Summary

We want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.

Detailed description

Patients with type 2 diabetes mellitus (T2DM) are not able to suppress their glucagon secretion after a meal or after ingestion of glucose. Previous studies have shown that gastrointestinal hormones might play a role in this phenomenon. However, it has not yet been possible to determine whether this lack of glucagon suppression postprandially results in an increased endogenous glucose secretion, and thus is a factor in the patients postprandial hyperglycemia. We aim to perform oral glucose tolerance tests and isoglycemic intravenous glucose infusions with and without a continuous glucagon infusion in patients with T2DM and healthy control subjects. The glucagon infusion is aiming at copying the inappropriate "physiological" glucagon response observed in patients with T2DM.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
BIOLOGICAL	isoglycemic intravenous glucose infusion and Glucagon infusion, day C	Infusion of 0.8ng/kg/min glucagon from time 0-25min
BIOLOGICAL	Oral glucose tolerance test, day A
BIOLOGICAL	intravenous iv glucose infusion, day B

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-09-01
• Completion: 2015-08-01
• First posted: 2013-12-13
• Last updated: 2015-12-02

Locations

1 site across 1 country: Denmark